Clearside Biomedical

Clearside Biomedical Receivables

Delisted

The Accounts Receivable of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 507,000.00 USD. In the previous year, Accounts Receivable was 170,000.00 USD — a change of 198.24% (higher).

Receivables

507,000.00USD

YoY

198.24%

Last updated:

Accounts Receivable of Clearside Biomedical is 2024 507,000.00 USD. Accounts Receivable of Clearside Biomedical was 2023 170,000.00 USD. It decreases by 198.24% higher compared to the previous year.

The Clearside Biomedical Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2021
10.00 M USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
170,000.00 USD
Jan 1, 2024
507,000.00 USD
The Clearside Biomedical Receivables history
YEARReceivablesYoY
507,000.00USD+198.24%
170,000.00USD—
0.00USD-100.00%
10.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Accounts Receivable of Clearside Biomedical is 507,000.00 USD in 2024.

Accounts Receivable of Clearside Biomedical changed from 170,000.00 USD to 507,000.00 USD, representing a 198.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Clearside Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Clearside Biomedical

All Key Metrics — Clearside Biomedical